Composition for prophylaxis and treatment of anemia in agricultural animals and poultry

FIELD: veterinary science.

SUBSTANCE: invention relates to a composition used in prophylaxis and treatment of anemia in agricultural animals and poultry that comprises a mixture of chelates of iron, copper, zinc, cobalt, sodium, calcium with ethylenediamine-N,N'-disuccinic acid in the following ratio of components, wt.-%: copper chelates with ethylenediamine-N,N'-disuccinic acid, 0.45-0.60; zinc chelates with ethylenediamine-N,N'-disuccinic acid, 1.40-1.45; cobalt chelates with ethylenediamine-N,N'-disuccinic acid, 0.075-0.08; sodium chelates with ethylenediamine-N,N'-disuccinic acid 42.0-44.0; calcium chelates with ethylenediamine-N,N'-disuccinic acid, 12.0-13.0, and iron chelates with ethylenediamine-N,N'-disuccinic acid, the balance. Agent provides enhancing the blood hemoglobin content in animals by 28% as compared with animals receiving neither anti-anemic agents and by 12% as compared with animals receiving the preparation-analog.

EFFECT: enhanced effectiveness of composition.

4 tbl, 4 ex

 

The invention relates to agriculture, in particular the production of therapeutic and prophylactic agent for diseases associated with lack of iron in the body of farm animals and poultry.

Known composition for the prevention and treatment of anemia of farm animals and poultry, including salts of iron, copper, zinc, cobalt and manganese (A.S. USSR 619186, BI No. 30, 1978).

Known composition for the prevention and treatment of anemia of farm animals and poultry, including salts of iron, copper, cobalt, alkali and alkaline-earth metals in the form of the drug "Inevita" (as the USSR 700131, B. I. No. 44, 1979).

Also known composition for the prevention and treatment of anemia of farm animals and poultry, including salts of iron, copper, cobalt, alkali and alkaline-earth metals in the form of the drug "Gambit-M (RF Patent 2097045, 1997, And 61 To 33/32) prototype.

A disadvantage of the known compositions is that the absorption of iron and trace elements is not fully.

The technical result of the invention is to increase the efficiency of absorption of iron in combination with trace elements from the target product in a living organism with anemia.

The technical result is achieved by creating a composition for the prevention and treatment of anemia of farm animals and poultry, represent the work of a mixture of complexions iron, copper, zinc, cobalt, sodium, calcium with Ethylenediamine-N,N'-dinternal acid in the following ratio, wt.%:

complexant copper with Ethylenediamine-N,N'-dinternal
acid0,45-0,60
complexant zinc with Ethylenediamine-N,N'-dinternal
acid1,40-1,45
complexant cobalt with Ethylenediamine-N,N'-dinternal
acidof 0.075 to 0.08
complexant sodium with Ethylenediamine-N,N'-dinternal
acid42,0-44,0
complexant calcium with Ethylenediamine-N,N'-dinternal
acid12,0-13,0
complexant iron with Ethylenediamine-N,N'-dinternal
acidthe rest of it.

The song is called "Tianamin".

You know getting complexant copper with Ethylenediamine-N,N'-dinternal acid (Journal of inorganic chemistry, 1971, t.16., VIP, str), complexant zinc with Ethylenediamine-N,N'-dinternal acid (Journal of inorganic chemistry, 1989, t, issue 1, str), complexant cobalt with Ethylenediamine-N,N'-diantar the Oh acid (Journal of inorganic chemistry, 1973, Vol.18, issue 1, str), complexant sodium with Ethylenediamine-N,N'-dinternal acid (Journal of inorganic chemistry, 1984, t, VIP, str). complexant calcium with Ethylenediamine-N,N'-dinternal acid (Journal of inorganic chemistry, 1971, t.16. 4 str), complexant iron with Ethylenediamine-N,N'-dinternal acid (Journal of inorganic chemistry, 1984, t, VIP, str).

In the patent and scientific literature unknown solutions similar claimed, i.e. the proposal meets the criteria of the invention of "novelty."

The claimed composition solves the current problem of veterinary prevention and treatment of anemia of farm animals and poultry, i.e. the sentence "industrially applicable".

Adopted for the prototype drug (Gambit M") are complexes of sodium salt Ethylenediamine-N,N'-dinternal acid with a number of metals, where the structural formula of the Ethylenediamine-N,N'-dinternal acid straightforward:

In the stated case, the Ethylenediamine-N,N'-dinternal acid, upon receipt of the stated complexions cyclists and presumably has the structure:

allowing complexions more actively than in the prototype to get involved in the metabolism in the body.

In addition, the proposed composition advantageously otlichaetsya of the prototype, that is a concatenation of individual complexions metals (copper, zinc, cobalt, sodium, calcium and iron) with EDAC, not by merging the solutions of the sodium salts of ADAK with the chlorides or sulfates of the respective metals (Gambit M"). Thus, the advantage of the composition in this case is that there is no ballast inorganic salts in the form of chlorides or sulfates of sodium, formed by merging the solutions of the components in the prototype by the reaction:

Na2ADAC+MeCl2→Meddac+2NaCl or

Na2ADAC+MeSO4→Meddac+Na2SO4,

where Me is the General designation of the metals (copper, zinc, cobalt, manganese and iron).

In the total mass of the drug "Gambit M" (in terms of 100 kg of dry product) when using metals as chlorides, you must use 136,187 kg of the drug content 36,187 kg ballast (in the form of the chloride ions), i.e. 36,187/136,187·100%=26,57%, which means the content in the composition of the drug more than 1/4 unnecessary (and sometimes harmful) substances. When using sulfates of metals of this indicator for ballast and above: 48,927/148,927·100%=32,85%, ie, the drug is almost 1/3 consists of useless (and sometimes harmful) salts of sulfuric acid.

These advantages allow to obtain a technical result of the invention.

The prior art does not know that the using of the above metals in the form of complexions the Ethylenediamine-N,N'-dinternal acid as a means of transport of trace elements leads to rapid absorption, that increases the absorption of iron and trace elements of the target product when introduced into a living organism from the outside. We first showed that the combined use of complexions above the Ethylenediamine-N,N'-dinternal acids, in specific ratios, improves therapeutic and prophylactic properties of the target product, leads to a rapid achievement of the technical result. Therefore, the invention meets the criterion of "inventive step".

The invention is illustrated in the following examples.

Example 1. Mix complexant copper with Ethylenediamine-N,N'-dinternal acid (0.45 kg), complexant zinc with Ethylenediamine-N,N'-dinternal acid (1.4 kg), complexant cobalt with Ethylenediamine-N,N'-dinternal acid (0,075 kg), complexant sodium with Ethylenediamine-N,N'-dinternal acid (42,0 kg), complexant calcium with Ethylenediamine-N,N'-dinternal acid (12 kg) and complexant iron Ethylenediamine-N,N'-dinternal acid (44,075 kg) receiving structure 1 in the following ratio, wt.%: complexant copper with Ethylenediamine-N,N'-dinternal acid - 0,45; complexant zinc with Ethylenediamine-N,N'-dinternal acid - 1,40; complexant cobalt with Ethylenediamine-N,N'-dinternal acid - 0,075; complexant sodium with Ethylenediamine-N,N'-dinternal acid - 42,0; complexant calcium with Ethylenediamine-N,N dinternal acid - 12,0; complexant iron Ethylenediamine-N,N'-dinternal acid - rest.

Example 2. Mix complexant copper with Ethylenediamine-N,N'-dinternal acid (0.60 kg), complexant zinc with Ethylenediamine-N,N'-dinternal acid (1.45 kg), complexant cobalt with Ethylenediamine-N,N'-dinternal acid (0.08 kg), complexant sodium with Ethylenediamine-N,N'-dinternal acid (44,0 kg), complexant calcium with Ethylenediamine-N,N'-dinternal acid (13 kg) and complexant iron with Ethylenediamine-N,N'-dinternal acid (40,87 kg) receiving part 2 in the following ratio, wt.%: complexant copper with Ethylenediamine-N,N'-dinternal acid - 0,60; complexant zinc with Ethylenediamine-N,N'-dinternal acid - 1,45; complexant cobalt with Ethylenediamine-N,N'-dinternal acid - 0,08; complexant sodium with Ethylenediamine-N,N'-dinternal acid - 44,0; complexant calcium with Ethylenediamine-N,N'-dinternal acid - 13,0; complexant iron with Ethylenediamine-N,N'-dinternal acid - rest.

Example 3. Mix complexant copper with Ethylenediamine-N,N'-dinternal acid (0.525 kg), complexant zinc with Ethylenediamine-N,N'-dinternal acid (1,425 kg), complexant cobalt with Ethylenediamine-N,N'-dinternal acid (0,0775 kg), complexant sodium with Ethylenediamine-N,N'-dinternal acid (43,0 kg), complexant calcium with Ethylenediamine-N,N'-dinternal acid (12.5 kg) and is elecont iron with Ethylenediamine-N,N'-dinternal acid (42,4725 kg) receiving part 3 in the following ratio of components, wt.%: complexant copper with Ethylenediamine-N,N'-dinternal acid - 0,525; complexant zinc with Ethylenediamine-N,N'-dinternal acid - 1,425; complexant cobalt with Ethylenediamine-N,N'-dinternal acid - 0,0775; complexant sodium Ethylenediamine-N,N'-dinternal acid - 43,0; complexant calcium Ethylenediamine-N,N'-dinternal acid - 12,5; complexant iron Ethylenediamine-N,N'-dinternal acid - rest.

The achievement of the technical result of the effectiveness of the proposed solution is tested on the model in vivo in the female burrows and their offspring. They determined the level of hemoglobin in the blood, females - productivity and puppies - live weight.

The research was conducted in 5 groups pastel females of the second year of the same weight, healthy 50 goals in each.

1-3 group - experimental group received a single diet with the introduction of compounds 1-3, obtained in accordance with examples 1-3;

group 4 - vivary control, received a common diet;

5 group - control group, received a common diet with the introduction of well-known tools "Gambit-M;

Supplements are claimed and known compounds were administered daily in the morning feeding in the same dosage of 20 mg per kg body weight. The results are shown in table 1 and 2.

Table 1.

Soda is the content of hemoglobin in the blood of females, mg%.
The follow-up period12345
February17,3017,2817,2917,2817,30
March17,1617,3917,4115,04the value of 16,81
April17,0117,7017,2013,8016,03

Tested the claimed compositions showed that the hemoglobin content in blood of the test animals when administered orally "Dienamine" is superior to 3.21% of compared data obtained in animals without additives, and 0.98% in comparison with the groups of animals when using the prototype. Output pups per female mink oral introduction "Dienamine" excels at 22-26% in comparison with the data of the prototype.

The experiments were continued in the offspring of Wistar females. From each group of females were selected on 50 puppies, for which observations had been conducted within 6 months from may to October. Supplements are claimed and known compounds were administered daily in the morning feeding in one dosage is 15 mg per kg body weight. The puppies were saved number of maternal groups (tables 3 and 4).

Table 3.

The hemoglobin content in the blood of puppies, mg%.
The follow-up period12345
June16,0316,0716,0814,4215,90
July16,1516,3816,4015,0316,07
August16,7017,0017,0215,6816,68
September16,9717,4017,4416,1916,96
October17,4017,5117,5316,6717,08

Table 4.

Change of body weight of the pups in,
The follow-up period12345
June224225223190203
July743758749638723
August908920913807904
September9931010995898983
October1119112311179311100

Tested the claimed compositions showed that the hemoglobin content in blood of the test animals when administered orally "Dienamine" exceeds 4-5% in comparison with the data received on the puppies without additives, and by 1.8% to 2.6% compared with the groups of animals when using the prototype. In addition, the live weight of pups of the test animals when administered orally "Dienamine" exceeds 4-5% in comparison with the data received on the puppies without additives, and by 1.5-2.0% in comparison with the groups of animals when using the prototype

Similar data were obtained when feeding the claimed composition of the Chicks from the calculation of 15-20 mg per kg body weight, in particular: the hemoglobin content in the blood was increased by 6.2% compared with the control group (nepoluchaetsa additives) and 0.9 to 1.7% compared with the control group, treated as an additive to feedstuff composition prototype, live weight of chickens in experimental groups treated with the compounds 1-3, obtained according to examples 1-3, increased by 7.5-9% compared with the control group (not treated with additives) and 1.8-4.8% compared with control what Ruppel, treated as an additive to feedstuff composition prototype.

When feeding of the proposed structure to the piglets at a rate of 15-20 mg per kg body weight were obtained the following results, in particular: the hemoglobin content in the blood was increased by 7.1-8.2 percent compared with the control group (nepoluchaetsa additives) and 1.2-1.8% compared with the control group, treated as an additive to feedstuff composition prototype, live weight of chickens in experimental groups treated with the compounds 1-3, obtained according to examples 1-3, increased by 10.1-15.6% compared with the control group (nepoluchaetsa additives) and 1.9-7.9% in comparison with the control group, treated as an additive to feedstuff composition prototype.

Thus, the use of the claimed compositions Tianamin effectively eliminates the deficiency of micronutrients in the body due to their rapid absorption, which leads to the rapid achievement of a technical result.

Composition for the prevention and treatment of anemia of farm animals and poultry, which is a mixture of complexions iron, copper, zinc, cobalt, sodium, calcium with Ethylenediamine-N,N'-dinternal acid in the following ratio, wt.%:

Complexant copper with Ethylenediamine-N,N'-dinternal
0,45-0,60
Complexant zinc with Ethylenediamine-N,N'-dinternal
acid1,40-1,45
Complexant cobalt with Ethylenediamine-N,N'-dinternal
acidof 0.075 to 0.08
Complexant sodium with Ethylenediamine-N,N'-dinternal
acid42,0-44,0
Complexant calcium with Ethylenediamine-N,N'-dinternal
acid12,0-13,0
Complexant iron with Ethylenediamine-N,N'-dinternal
acidRest



 

Same patents:

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a liquid pharmaceutical composition comprising pegilated erythropoietin as a conjugate in pharmaceutically acceptable buffer at pH from 5.5 to 7.0 and optionally one or some pharmaceutically acceptable excipients. Proposed composition is used in treatment and prophylaxis of diseases associated with erythropoiesis injury. The advantage of invention involves enhancing stability of the preparation.

EFFECT: improved and valuable property of preparation.

59 cl, 4 tbl, 11 dwg, 13 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a medicinal agent used in prophylaxis and treatment of asiderotic anemia. The preparation comprises components in their following ratio: ferbitol, 80-99%, and gelatin, 1-20%. Invention provides reducing toxicity of the prepared preparation, improvement of its biological activity that results to enhancing therapeutic effectiveness.

EFFECT: enhanced and valuable medicinal properties of agent.

6 ex

FIELD: medicine, pharmacology.

SUBSTANCE: agent for stimulation of erythropoiesis and elimination of iron deficiency comprises hemoglobin obtained from animal blood containing methemoglobin additionally. The ratio of hemoglobin and methemoglobin in the agent = (25-75)-(75-25) wt.-%. The agent shows the expressed heme-stimulating effect. The agent can be used in producing medicinal agents and biologically active supplements.

EFFECT: valuable medicinal properties of agent.

4 dwg

FIELD: medicine, veterinary science, pharmacy.

SUBSTANCE: invention relates to the iron-containing preparation "Ferral". Iron-containing preparation "Ferral" comprises iron in bivalent form - hydroxy-ferrous oxide in the concentration 2-9%. Invention provides administration of the preparation in amount practically by 10 times less as compared with administration of the known preparations that shows the sufficient effect and doesn't cause over dosing.

EFFECT: improved and valuable properties of preparation.

3 tbl, 4 ex

FIELD: medicine, immunology.

SUBSTANCE: invention relates to anemia treatment in infants with immunodeficiency condition. Claimed method includes alternation of tonsilgon H administration in dose of 25 drops 3 times per day for 2 weeks and IRS-19 in one dose in each nasal passage 2 times per day for 2 weeks during 3 months. Course is carried out 2 times per year in spring and autumn for two years on end. In addition to abovementioned preparations 1 ml of tymogen is administered intramuscularly 2 times per week, 2 ml of 12.5 % cycloferon is administered intramuscularly 1 time per week, 2 ml of erytrostim is administered percutaneously 1 time per week during 3 months 2 times per year in spring and autumn for two years on end.

EFFECT: method for effective recovery of red blood shoot and immunodeficiency immunopoesis.

1 tbl, 1 ex

FIELD: medicine, pediatrics, hematology.

SUBSTANCE: the present innovation could be applied in treating surgical and oncological diseases in children during treating and preventing anemia of different etiology. One should introduce ceruloplasmin at daily single dosage ranged 50-200 mg depending upon child's age against 100-200 ml 0.9%-sodiumchloride solution intravenously by drops at the rate of 40-50 drops/min. Moreover, for preventing and/or treating posthemorrhagic anemia in case of surgical operations one should introduce ceruloplasmin during 2 d before surgical operation, intraoperationally, and for 2-10 d after operation. For preventing and/or treating anemia in case of purulent-septic diseases ceruloplasmin should be introduced during chemotherapeutic days during the whole period of the course conducted, for preventing and treating radiation anemia at the background of radiation therapy ceruloplasmin should be injected once weekly during the whole period of radiotherapy course, for preventing and treating toxic and radiation anemia at the background of chemoradiation therapy ceruloplasmin should be introduced once weekly on the day of chemotherapy during the whole course of chemoradiation treatment. The innovation enables to avoid inflows of erythrocytic mass and donor's blood along with shortened number of procedures on introduction of ceruloplasmin and 4-times decrease in the risk for the development of severe anemia in children due to matching peculiar mode for ceruloplasmin introduction.

EFFECT: higher efficiency of therapy and prophylaxis.

4 cl, 5 ex

FIELD: agriculture, animal husbandry, fur farming.

SUBSTANCE: invention relates to preparations used in prophylaxis and treatment of domestic and agricultural animals and for maintaining trace elements composition of fodders. The preparation allows balancing the nutrition diet for animals with the optimal ratio of trace elements providing prophylaxis of many diseases. Proposed preparation comprising complex of iron, manganese, copper, cobalt, selenium and zinc with ethylenediamine-N,N1-disuccinic acid disodium or dipotassium salt and water comprises additionally iodine in the following ratio of components: ethylenediamine-N,N1-disuccinic acid disodium or dipotassium salt, 15-25; iron (III), 1.5-5.5; manganese (II), 0.25-3.0; copper (II), 0.12-0.55; cobalt (II), from above 0.05 to 0.3; zinc (II), 0.05-1.5; selenium (IV), from above 0.03 to 0.06; iodine (I), 0.01-0.08; water, the balance.

EFFECT: improved and valuable properties of preparation.

1 cl, 4 tbl

FIELD: medicine.

SUBSTANCE: invention proposes an agent for correction of disturbances in production of cytokines and markers of activation of immune system cells in chronic iron-deficient anemia. Agent represents Sorbifer Durules known early as preparation used in treatment of iron-deficient anemia. Invention provides recovering the level of anti-inflammatory cytokines (IL-1, IL-6, IL-8, FNO-α, INF-α and INF-γ) and normalization of cellular immunity by indices of markers CD-25, CD-71 and CD-34.

EFFECT: valuable medicinal properties of agent.

2 tbl, 1 ex

FIELD: veterinary.

SUBSTANCE: agent is based on complex compound of colloidal iron liganded by polyoxymethylene-lauric alcohol and contains following components, mg: colloidal iron 50.0-60.0, lauric alcohol 0.1-0.3, copper 0.1-0.3, zinc 0.1-0.3, cobalt 0.1-0.3, selenium 0.001-0.005, and water to 1000. Agent can further contain 30.0-50.0 mg glucose and 0.1-0.6 mg polyvinyl alcohol.

EFFECT: enabled therapeutical and preventive efficiency at low toxicity, the same dispersity, and high stability upon storage.

3 tbl, 7 ex

FIELD: pharmaceutics, veterinary science.

SUBSTANCE: the present innovation deals with preventing and treating hypomicroelementosis in different farm and domestic animals, furred animals, and, also, for enhancing the growth in animals, and treating a number of specific diseases and, also, for maintaining microelemental composition of feedstuffs. The suggested preparation includes chelated complex of iron, manganese, zinc, copper, cobalt, selenium and iodine with organic ligand of complexone type and water. According to the innovation as a chelation ligand it contains trisodium salt of methionine succinic (α-amino-γ-methylthiobutyric-N-succinic) acid at a certain ratio of components. The innovation provides to obtain preparation in soluble form being capable to be well digested by the animal.

EFFECT: higher efficiency.

FIELD: veterinary science.

SUBSTANCE: the present innovation deals with applying a multi-purpose complex preparation that contains the following components in 1 l of distilled water: sodium selenite 1.0; vitamin E/in the form of combinal E/7500 mg; succinic acid 10.0; zinc sulfate 10.0 and pharmazine 50000 U. The preparation should be introduced as intramuscular injections 45, 30, 15 d before delivery and during the day of delivery: in cows per 10-15 ml, for pigs and sheep per 5 ml, for youngsters after the birth: in calves - 5 ml, in piglets and lambs per 1-2 ml, in hens per 0.5 ml once/2 wk. The innovation is very efficient in increasing the quality and quantity of production, improving the growth and development in fetus and offspring, preventing some surgical and obstetric-gynecological pathologies.

EFFECT: higher efficiency of correction.

5 cl

FIELD: organic chemistry, medicine, dermatology.

SUBSTANCE: invention relates to zinc and aliphatic halogen-carboxylic acid salts that can be used in treatment of benign neoplasms of skin and visible mucosa tissues. Invention proposes the following formula of zinc and aliphatic halogen-carboxylic acid salts: (1): wherein R means -CHal3, -CHHal2, -CH2Hal and (2): wherein R' means Alk, hydrogen atom (H); R'' means Hal; R' means Alk; R'' means H, Alk wherein in these formulae halogen atom can be represented by fluorine atom (F), chlorine atom (Cl), bromine atom (Br) or iodine atom (J). Invention provides the development of original preparation used in treatment of benign neoplasms of skin and visible mucosa tissues with low toxicity, rapid effect, expressed therapeutic effect and eliciting good tolerance, absence of complications in treatment, healing without formation of scar tissue. The development of the preparation provides expanding assortment of agents used in treatment of such diseases.

EFFECT: enhanced and valuable properties of agents.

13 ex

The invention relates to the application of certain monoalkyl esters of fumaric acid or in the form of their salts or in the form of the free acid, individually or in combination with dialkylamino, to obtain pharmaceutical compositions for use in transplantation medicine

The invention relates to containing certain monoalkyl esters of fumaric acid in the form of salts or the free acid individually or in combination with dialkylamino for the treatment of arthritis or multiple sclerosis, as well as reactions "graft versus host"

Medical center // 2194523
The invention relates to medicine and relates to compositions for the prevention of nervous disorders and asthenic States of different etiology and resolve emotional or functional disorders caused by these conditions
The invention relates to medicine, namely to methods provide emergency self - help and mutual aid and can be used to prevent complications from snake bites in field conditions
The invention relates to physical therapy and is intended for treatment of a dysbacteriosis of intestines

The invention relates to the field of veterinary pharmacology and can be used for the prevention and treatment of hypochromic microcytic anemia

Drug // 2121347

FIELD: pharmaceutical engineering; medical engineering.

SUBSTANCE: method involves carrying out nuclear magnetic resonance tomography of human or animal blood circulation system containing chelating ion complexes of bivalent and valence three paramagnetic metals of (I)X-L-Y formula, where X is the polyamide carbonyl ligand residue and Y is the gallic acid derivative, .

EFFECT: high accuracy of diagnosis.

28 cl

Up!